Regular doses of a widely used fertility drug may help to boost cognitive skills in people with Down’s syndrome, a pilot study led by researchers from France and Switzerland has suggested.
This content was published on
2 minutes
CHUV/Guardian/swissinfo/sb
Português
pt
Cientistas identificam hormônio chave que pode ajudar pessoas com síndrome de Down
In a small-scale trial, researchersExternal link fitted seven men who have Down’s syndrome with a pump that provided a dose of GnRH, a gonadotropin-releasing hormone, every two hours for six months.
Six out of the seven men showed moderate cognitive improvements after the treatment, including in attention and being able to understand instructions, compared with a control group who were not given the hormone.
The team from the Lille Neuroscience & Cognition laboratory and Lausanne University Hospital (CHUV) behind the work said brain scans of the participants, who were aged between 20 and 37, given the hormone suggest they underwent changes in neural connectivity in areas involved in cognition.
“[People] with Down’s syndrome have cognitive decline which starts in the 30s,” Professor Nelly Pitteloud, co-author of the study from the University of Lausanne, told The Guardian. “I think if we can delay that, this would be great, if the therapy is well tolerated [and] without side effects.”
Down syndrome, also known as trisomy 21, is the most common genetic cause of intellectual disability, affecting about one in 800 babies. It occurs when a person is born with an extra copy of chromosome 21. Down syndrome results in a variety of clinical manifestations, including decline in cognitive capacity. With age, 77% of people with the condition experience symptoms similar to those of Alzheimer’s disease. Gradual loss of the ability to smell is also common.
The researchers previously found mice with an extra copy of chromosome 16 experienced an age-related decline in cognition and sense of smell, similar to that seen in people with Down’s syndrome. In a series of experiments, the team found regular doses of gonadotropin-releasing hormone boosted both the sense of smell and cognitive performance of these mice.
Their work was published in Science journal on September 1.
Following these promising findings, the researchers are considering the launch of a larger study – with the inclusion of women – to confirm the efficacy of this treatment in people with Down syndrome, but also for other neurodegenerative conditions such as Alzheimer’s disease.
Popular Stories
More
Climate adaptation
Why Switzerland is among the ten fastest-warming countries in the world
Is your place of origin, your Heimatort, important to you?
Every Swiss citizen has a Heimatort, a place of origin, but many have never visited theirs. What’s your relationship with your Heimatort? What does it mean to you?
Common species vital for stability of food webs, study shows
This content was published on
The loss of common flora and fauna can make food webs unstable, with big consequences for entire ecosystems, a Swiss study has shown.
This content was published on
Overall spending on building fell slightly last year, with trends showing more money flowing into renovations than new buildings.
This content was published on
Foreign trade dipped from April to June in terms of exports and imports, with the trend largely driven by the chemicals and pharma sector.
Former Vatican auditor cleared of bribery in Zurich trial
This content was published on
The Zurich District Court acquitted a former financial markets supervisor at the Vatican of charges of corruption and bribery.
This content was published on
The President of the Swiss Conference of Bishops wants a national digital register of clergy – in the interest of transparency.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.